Oxford Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Oxford Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-802	Closed	-$230K	–	785
2019 Q4	$230K	Sell	802 -788	-50%	-$171K	0.01%	1513
2019 Q3	$229K	Buy	+1,590	New	+$216K	0.01%	1542
2018 Q4	–	Sell	-1,317	Closed	-$335K	–	1936
2018 Q3	$335K	Buy	+1,317	New	+$364K	0.01%	1468
2016 Q1	–	Sell	-1,666	Closed	-$333K	–	849
2015 Q4	$333K	Buy	+1,666	New	+$361K	0.01%	742

Other funds holding KPTI

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Oxford Asset Management's KPTI Position: Q1 2020 in Review

Oxford Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2020, closing a stake of 802 shares — an estimated $230K sold.

Oxford Asset Management first reported a position in KPTI in Q4 2015 and held it in 4 quarters. The position peaked at $335K in Q3 2018. 136 funds tracked by Wall St. Rank hold KPTI as of Q1 2020.

Oxford Asset Management reported no remaining Karyopharm Therapeutics position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 802 Karyopharm Therapeutics shares in Q1 2020, an estimated $230K.
Oxford Asset Management first reported a position in Karyopharm Therapeutics in Q4 2015 and held it in 4 quarters.
Oxford Asset Management's Karyopharm Therapeutics position peaked at $335K in Q3 2018.
136 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.